According to the North China Pharmaceutical announcement, the cumulative daily closing price increase deviation value of the company's stock reached 20% for 3 consecutive trading days on September 30, October 8, and October 9, 2026, which is an abnormal fluctuation in stock trading. Recently, the market has paid a lot of attention to hot concepts related to “plague”. The company's injectable streptomycin sulfate includes plague treatment. This product is a traditional antibiotic variety. The sales revenue scale for 2025 and January-June 2026 is small, and it will not have a significant impact on the company's overall business performance. After self-inspection and verification with the controlling shareholders and actual controllers, there were no important matters that should be disclosed but not disclosed, and none of the directors, supervisors, controlling shareholders, and their concerted actions traded the company's shares. As of October 9, 2026, the company's rolling price-earnings ratio was 83.84 times, significantly higher than the rolling price-earnings ratio of the pharmaceutical manufacturing industry of 26.71 times. Investors are invited to pay attention to investment risks.

According to the North China Pharmaceutical announcement, the cumulative daily closing price increase deviation value of the company's stock reached 20% for 3 consecutive trading days on September 30, October 8, and October 9, 2026, which is an abnormal fluctuation in stock trading. Recently, the market has paid a lot of attention to hot concepts related to “plague”. The company's injectable streptomycin sulfate includes plague treatment. This product is a traditional antibiotic variety. The sales revenue scale for 2025 and January-June 2026 is small, and it will not have a significant impact on the company's overall business performance. After self-inspection and verification with the controlling shareholders and actual controllers, there were no important matters that should be disclosed but not disclosed, and none of the directors, supervisors, controlling shareholders, and their concerted actions traded the company's shares. As of October 9, 2026, the company's rolling price-earnings ratio was 83.84 times, significantly higher than the rolling price-earnings ratio of the pharmaceutical manufacturing industry of 26.71 times. Investors are invited to pay attention to investment risks.